Related Experiment Videos
Magnesium in cardiac arrest (the magic trial).
D M Fatovich1, D A Prentice, G J Dobb
1Department of Emergency Medicine, Royal Perth Hospital, WA, Australia.
Resuscitation
|April 15, 1999
Summary
High-dose magnesium did not improve survival rates for out-of-hospital cardiac arrest (OHCA) patients in a randomized trial. Early defibrillation remains critical for ventricular fibrillation (VF) survival.
Area of Science:
- Emergency Medicine
- Cardiology
- Clinical Trials
Background:
- Out-of-hospital cardiac arrest (OHCA) carries a poor prognosis.
- Emerging evidence suggested high-dose magnesium might enhance survival rates.
- The emergency department (ED) is a critical setting for initial OHCA management.
Purpose of the Study:
- To evaluate the efficacy of high-dose magnesium sulfate (MgSO4) as a first-line therapy for OHCA of cardiac origin.
- To compare survival outcomes between patients receiving magnesium and placebo during advanced cardiac life support (ACLS).
Main Methods:
- A prospective, randomized, double-blind, placebo-controlled trial was conducted.
- 67 OHCA patients received either 5g MgSO4 or a placebo intravenously.
- Outcomes included ECG rhythm, return of spontaneous circulation (ROSC), and survival at various stages.
Main Results:
- No significant differences in ECG rhythm, ROSC, or survival to ED discharge between magnesium and placebo groups.
- One patient in the magnesium group survived to hospital discharge; none in the placebo group survived.
- More witnessed arrests occurred in the magnesium group (35% vs 11%).
Conclusions:
- High-dose magnesium as first-line therapy for OHCA did not significantly improve survival.
- Early defibrillation is the most crucial intervention for ventricular fibrillation (VF).
- Further research is needed to clarify magnesium's role in cardiac and cerebral resuscitation.